Nov 20, 2026 · 2 min readIncretin AnalogsClinical Trials
Semaglutide in Children 6 to <12: What the STEP Young Phase 3 Trial Measured
STEP Young, a phase 3 NEJM trial in 167 children aged 6 to <12, reported BMI change of -13.5% with semaglutide vs +2.7% with placebo at week 68.

The New England Journal of Medicine published online on 16 November 2026 the results of STEP Young, a phase 3 trial of once-weekly subcutaneous semaglutide in children aged 6 to under 12 years with obesity (Jastreboff et al.). In the trial, body-mass index (BMI) fell by 13.5% at week 68 in the semaglutide group, while it rose by 2.7% in the placebo group. The trial was funded by Novo Nordisk.
What happened
Semaglutide is approved for the treatment of obesity in adolescents and adults, according to the paper, but data in younger children were lacking. STEP Young tested it in children aged 6 to under 12, a group for which medical options are limited. The paper describes childhood obesity as a chronic, neurometabolic disease.
Design and population
STEP Young (ClinicalTrials.gov NCT05726227) was a randomized, double-blind, placebo-controlled phase 3 trial. Of 167 children randomized 2:1, 112 were assigned to semaglutide and 55 to placebo. Treatment lasted 104 weeks and was followed by a 7-week washout period. Both groups received lifestyle-modification counseling. The primary end point was percent change in BMI from baseline to week 68; the confirmatory secondary end point was a reduction in BMI category at week 68.
The numbers
- Week 68 BMI change: -13.5% with semaglutide vs +2.7% with placebo; estimated difference -16.2 percentage points (95% CI -19.4 to -12.9; P<0.001).
- Week 104 BMI change: -9.4% vs +8.4%; difference -17.8 percentage points (95% CI -22.2 to -13.3).
- BMI category: at week 68, a reduction in BMI category occurred in 79% of semaglutide participants vs 23% of placebo participants (odds ratio 7.8; 95% CI 3.5 to 17.6; P<0.001).
- Below the obesity threshold: BMI fell below the 95th percentile for age and sex in 38% of the semaglutide group and 2% of the placebo group.
Safety
Adverse events occurred in 96% of participants receiving semaglutide and 93% of those receiving placebo. Gastrointestinal events were the most common and occurred more often with semaglutide than with placebo. One participant in the semaglutide group discontinued because of a gastrointestinal adverse event.
Context and what comes next
The authors conclude that, among children aged 6 to under 12 with obesity, 68 weeks of semaglutide produced a significantly greater mean percent reduction in BMI than placebo. STEP Young extends the STEP program, which previously studied semaglutide in adults and adolescents. The abstract does not report regulatory filings for this age group, and this article makes no statement about approval for children. A single trial in 167 children, sponsored by the manufacturer, will be read alongside longer-term safety and growth data.
Sources
Sources
For research use only. Not for human or animal consumption. This article summarizes published research for scientific information only. It is not medical advice and makes no claim about any use in people or animals. These products have not been evaluated or approved by the U.S. Food and Drug Administration (FDA). They are not intended to diagnose, treat or prevent any disease.